EUVIMEDEUVIMED entdecken
Crossref

SpaCBA ‐ OVA Liposome Reprograms Immune Tolerance to Ameliorate Allergic Rhinitis via DC ‐T Cell Crosstalk

Jinna Yang, Jinmei Xue, Lihua Mo, Aizhi Zhang, Jinbiao Xie, Jialiang Fan, Jianwen Zhong, Haiyang Han, Pingchang Yang iD, Dabo Liu, Xiangqian Luo

Immunology · 2025

DOI: 10.1111/imm.70078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, 2025. Verfasst von Jinna Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Otolaryngology, Shenzhen Hospital, Southern Medical University, Shenzhen, China. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Immune Tolerance, Ovalbumin, Dendritic Cells. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shenzhen Key Medical Discipline Construction Fund, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allergic rhinitis (AR) is a prevalent immune disorder driven by Th2‐polarised inflammation, with current therapies primarily providing symptomatic relief rather than addressing the underlying immune dysfunction. Allergen‐specific immunotherapy (AIT) holds promise for inducing long‐term tolerance but is limited by poor mucosal delivery, enzymatic degradation of antigens, and inconsistent efficacy. A liposomal formulation co‐encapsulating SpaCBA (probiotic protein) and ovalbumin (OVA) was engineered. Characterisation included in vitro/in vivo evaluations of immune modulation and therapeutic efficacy in a murine AR model. The SpaCBA‐OVA liposome exhibited stable characteristics (size: 100 ± 25 nm; zeta potential: −22 ± 3 mV; 85% entrapment efficiency) and enhanced proteolytic resistance (> 70% protein integrity after 48‐h trypsin exposure vs. > 90% degradation of free proteins). Bone marrow‐derived DCs (BMDCs) internalised the liposome 3–3.5× more efficiently via CD206/TLR2, adopting a semi‐mature (CD86low/MHC‐II high ) phenotype and secreting IL‐10 (320 ± 30 pg/mL) and TGF‐β (280 ± 25 pg/mL). RNA‐seq identified 980 differentially expressed genes in T cells, with upregulation of Treg markers (FOXP3, IL‐10) and downregulation of Th2 factors (GATA3, IL4). Epigenetic analysis confirmed 55% demethylation of the FOXP3 promoter. In AR mice, the liposome reduced sneezing and nasal rubbing by 60%–65% ( p < 0.001), decreased nasal eosinophils by 55%, normalised ZO‐1/occludin expression (90% of controls), and reduced epithelial permeability (FITC‐dextran flux). The SpaCBA‐OVA liposome enhances mucosal delivery and stability of antigens, reprograms DCs to induce Treg‐mediated tolerance via metabolic and epigenetic mechanisms, and effectively ameliorates AR pathology in mice. This formulation represents a promising targeted therapy for AR, addressing key limitations of current AIT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhinitis, AllergicImmune ToleranceOvalbuminDendritic CellsT-Lymphocytes, RegulatoryCell CommunicationAnimalsLiposomesMiceDisease Models, AnimalFemaleAllergensMice, Inbred BALB CDesensitization, Immunologic

Stichwörter der Autor:innen

SpaCBA‐OVA liposomeTreg polarisationallergic rhinitisdendritic cellsmucosal immunomodulation

Substanzen

LiposomesOvalbuminAllergens

Autor:innen und Institutionen

  • Department of Pediatric Otolaryngology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
  • Shenzhen School of Clinical Medicine, Southern Medical University, Shenzhen, China.
  • Department of Otolaryngology, Head & Neck Surgery, Second Hospital of Shanxi Medical University, Taiyuan, China.
  • Department of Critical Care Medicine, Second Hospital of Shanxi Medical University, Taiyuan, China.
  • State Key Laboratory of Respiratory Diseases Allergy Division at Shenzhen University and Institute of Allergy & Immunology, Shenzhen Key Laboratory of Allergy & Immunology, Shenzhen University School of Medicine, Shenzh…
  • Department of Otolaryngology, People's Hospital of Shenzhen Baoan District, The Second Affiliated Hospital of Shenzhen University, Shenzhen, China.

ORCID-Profile: Pingchang Yang

Förderung

  • National Natural Science Foundation of China
  • Shenzhen Key Medical Discipline Construction Fund
  • Natural Science Foundation of Guangdong Province
  • Science, Technology and Innovation Commission of Shenzhen Municipality
  • China Postdoctoral Science Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • State Key Laboratory of Respiratory Disease Research Fund
  • Shenzhen Hospital, Southern Medical University

Zitieren

APA

Yang, J., Xue, J., Mo, L., Zhang, A., Xie, J., Fan, J., Zhong, J., Han, H., Yang, P., Liu, D., & Luo, X. (2025). SpaCBA ‐ OVA Liposome Reprograms Immune Tolerance to Ameliorate Allergic Rhinitis via DC ‐T Cell Crosstalk. Immunology. https://doi.org/10.1111/imm.70078

Vancouver

Yang J, Xue J, Mo L, Zhang A, Xie J, Fan J, et al. SpaCBA ‐ OVA Liposome Reprograms Immune Tolerance to Ameliorate Allergic Rhinitis via DC ‐T Cell Crosstalk. Immunology. 2025. doi:10.1111/imm.70078

BibTeX
@article{Yang2025,
  author = {Yang, Jinna and Xue, Jinmei and Mo, Lihua and Zhang, Aizhi and Xie, Jinbiao and Fan, Jialiang and Zhong, Jianwen and Han, Haiyang and Yang, Pingchang and Liu, Dabo and Luo, Xiangqian},
  title = {SpaCBA ‐ OVA Liposome Reprograms Immune Tolerance to Ameliorate Allergic Rhinitis via DC ‐T Cell Crosstalk},
  journal = {Immunology},
  year = {2025},
  doi = {10.1111/imm.70078}
}
Kostenlos starten →